Literature DB >> 26915294

Histone deacetylase inhibition reveals a tumor-suppressive function of MYC-regulated miRNA in breast and lung carcinoma.

C M Adams1, C M Eischen1.   

Abstract

Histone deacetylase (HDAC) inhibition leads to dynamic changes in the epigenetic landscape that is postulated to alter the expression of critical mediators of cellular proliferation and death. While current HDAC inhibitors have shown to be efficacious in the treatment of specific hematologic malignancies, their therapeutic utility in epithelial-based cancers warrants further evaluation. Moreover, the mechanisms of HDAC inhibition-induced cancer cell death are not completely understood. Therefore, elucidation of the underlying pathways engaged by HDAC inhibition may enable the development of more effective therapeutic strategies. Here, we report that HDAC inhibition in human breast and lung carcinoma cells activates an apoptotic mechanism mediated by microRNA (miRNA) and induced by the oncogene MYC. Specifically, following HDAC inhibition, MYC, which normally represses miR-15 and let-7 families, transcriptionally activated their expression and MYC was required for this miRNA upregulation. As a result, transcript levels of the tumor-suppressive miR-15 and let-7 families increased, which targeted and decreased the expression of the crucial prosurvival genes BCL-2 and BCL-XL, respectively. MYC was also required for the downregulation of BCL-2 and BCL-XL following HDAC inhibition. Blocking the binding sites of the miR-15 and let-7 families in the 3'-untranslated regions of BCL-2 and BCL-XL protected against HDAC inhibition-induced apoptosis. These results provide important insight into the molecular underpinnings of HDAC inhibition-induced cell death in breast and lung cancer and reveal a tumor-suppressive role for MYC-regulated miRNA that is activated with HDAC inhibition.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26915294      PMCID: PMC4947678          DOI: 10.1038/cdd.2016.9

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  24 in total

1.  Elevated Mdm2 expression induces chromosomal instability and confers a survival and growth advantage to B cells.

Authors:  P Wang; T Lushnikova; J Odvody; T C Greiner; S N Jones; C M Eischen
Journal:  Oncogene       Date:  2007-09-10       Impact factor: 9.867

Review 2.  New and emerging HDAC inhibitors for cancer treatment.

Authors:  Alison C West; Ricky W Johnstone
Journal:  J Clin Invest       Date:  2014-01-02       Impact factor: 14.808

3.  Oncogenic protein MTBP interacts with MYC to promote tumorigenesis.

Authors:  Brian C Grieb; Mark W Gramling; Maria Pia Arrate; Xi Chen; Stephen L Beauparlant; Dale S Haines; Hua Xiao; Christine M Eischen
Journal:  Cancer Res       Date:  2014-05-01       Impact factor: 12.701

Review 4.  MicroRNAs in cancer.

Authors:  Gianpiero Di Leva; Michela Garofalo; Carlo M Croce
Journal:  Annu Rev Pathol       Date:  2013-09-25       Impact factor: 23.472

Review 5.  MYC on the path to cancer.

Authors:  Chi V Dang
Journal:  Cell       Date:  2012-03-30       Impact factor: 41.582

6.  MicroRNA expression profiles classify human cancers.

Authors:  Jun Lu; Gad Getz; Eric A Miska; Ezequiel Alvarez-Saavedra; Justin Lamb; David Peck; Alejandro Sweet-Cordero; Benjamin L Ebert; Raymond H Mak; Adolfo A Ferrando; James R Downing; Tyler Jacks; H Robert Horvitz; Todd R Golub
Journal:  Nature       Date:  2005-06-09       Impact factor: 49.962

7.  Widespread microRNA repression by Myc contributes to tumorigenesis.

Authors:  Tsung-Cheng Chang; Duonan Yu; Yun-Sil Lee; Erik A Wentzel; Dan E Arking; Kristin M West; Chi V Dang; Andrei Thomas-Tikhonenko; Joshua T Mendell
Journal:  Nat Genet       Date:  2007-12-09       Impact factor: 38.330

8.  A microRNA expression signature of human solid tumors defines cancer gene targets.

Authors:  Stefano Volinia; George A Calin; Chang-Gong Liu; Stefan Ambs; Amelia Cimmino; Fabio Petrocca; Rosa Visone; Marilena Iorio; Claudia Roldo; Manuela Ferracin; Robyn L Prueitt; Nozumu Yanaihara; Giovanni Lanza; Aldo Scarpa; Andrea Vecchione; Massimo Negrini; Curtis C Harris; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-03       Impact factor: 11.205

9.  miR-223 regulates cell growth and targets proto-oncogenes in mycosis fungoides/cutaneous T-cell lymphoma.

Authors:  Laura Y McGirt; Clare M Adams; Devin A Baerenwald; Jeffrey P Zwerner; John A Zic; Christine M Eischen
Journal:  J Invest Dermatol       Date:  2013-11-07       Impact factor: 8.551

10.  HDAC 1/4-mediated silencing of microRNA-200b promotes chemoresistance in human lung adenocarcinoma cells.

Authors:  Dong-Qin Chen; Ban-Zhou Pan; Jia-Yuan Huang; Kai Zhang; Shi-Yun Cui; Wei De; Rui Wang; Long-Bang Chen
Journal:  Oncotarget       Date:  2014-05-30
View more
  10 in total

1.  Molecular underpinnings of HDAC inhibition revealed.

Authors:  Clare M Adams; Christine M Eischen
Journal:  Cell Cycle       Date:  2016-05-06       Impact factor: 4.534

2.  BCL-W has a fundamental role in B cell survival and lymphomagenesis.

Authors:  Clare M Adams; Annette S Kim; Ramkrishna Mitra; John K Choi; Jerald Z Gong; Christine M Eischen
Journal:  J Clin Invest       Date:  2017-01-17       Impact factor: 14.808

Review 3.  MTBP and MYC: A Dynamic Duo in Proliferation, Cancer, and Aging.

Authors:  Brian C Grieb; Christine M Eischen
Journal:  Biology (Basel)       Date:  2022-06-08

4.  Prognostic value of Lin28A and Lin28B in various human malignancies: a systematic review and meta-analysis.

Authors:  Jiayi Zhang; Aiming Xu; Chenkui Miao; Jie Yang; Min Gu; Ninghong Song
Journal:  Cancer Cell Int       Date:  2019-04-02       Impact factor: 5.722

5.  Anticancer Effect of Rh2, a Histone Deacetylase Inhibitor, in HepG2 Cells and HepG2 Cell-Derived Xenograft Tumors Occurs via the Inhibition of HDACs and Activation of the MAPK Signaling Pathway.

Authors:  Shi Qing Qiang; Gao Chao Qin; Li Jing; Feng Zi Qiang; Qin Hong Mei; Chen Di Long
Journal:  Asian Pac J Cancer Prev       Date:  2021-08-01

6.  An integrative systems biology approach to overcome venetoclax resistance in acute myeloid leukemia.

Authors:  Michelle Przedborski; David Sharon; Severine Cathelin; Steven Chan; Mohammad Kohandel
Journal:  PLoS Comput Biol       Date:  2022-09-13       Impact factor: 4.779

7.  MYC-Induced miR-203b-3p and miR-203a-3p Control Bcl-xL Expression and Paclitaxel Sensitivity in Tumor Cells.

Authors:  Sofia Aakko; Anne Hege Straume; Einar Elvbakken Birkeland; Ping Chen; Xi Qiao; Per Eystein' 'Lønning; Marko J Kallio
Journal:  Transl Oncol       Date:  2018-10-22       Impact factor: 4.243

8.  Inhibition of miR-24 suppresses malignancy of human non-small cell lung cancer cells by targeting WWOX in vitro and in vivo.

Authors:  Xue-Hai Wang; Chong-Zhi Gan; Jia-Yong Xie
Journal:  Thorac Cancer       Date:  2018-10-11       Impact factor: 3.500

Review 9.  The network of non-coding RNAs and their molecular targets in breast cancer.

Authors:  Francesca Crudele; Nicoletta Bianchi; Eva Reali; Marco Galasso; Chiara Agnoletto; Stefano Volinia
Journal:  Mol Cancer       Date:  2020-03-18       Impact factor: 27.401

Review 10.  The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy.

Authors:  Guo Li; Yuan Tian; Wei-Guo Zhu
Journal:  Front Cell Dev Biol       Date:  2020-09-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.